Adversarial Injection · Glasdegib (Daurismo; PF-04449913; NDA 210674; CAS 1095173-27-5; MW ~432.4 g/mol; 1-[(2Z)-2-(1-methylpyrazol-4-yl)-2-[(3R)-1-(2-methylpyrimidin-5-yl)-3-piperidyl]methyl]-3-[2-(trifluoromethyl)phenyl]urea [THIRD SMO INHIBITOR in Glyphward 599-attack portfolio — SMO THREE-NDA-HOLDER CLASS NULL: vismodegib (Genentech; NDA 203388; #597) + sonidegib (Sun Pharma; NDA 205266; #598) + glasdegib (Pfizer; NDA 210674; #599) = THREE distinct NDA holders for SMO inhibitors; all three return CAS null on independent EHS platforms confirming SMO class as a three-NDA-holder OEL null; FIRST SMO INHIBITOR IN HEMATOLOGIC MALIGNANCY (AML): vismodegib (2012; BCC) and sonidegib (2015; BCC) both approved for BASAL CELL CARCINOMA of the skin; glasdegib (NDA 210674; November 21 2018) is the FIRST SMO inhibitor approved in a HEMATOLOGIC MALIGNANCY — specifically AML (acute myeloid leukemia) in combination with low-dose cytarabine (LDAC) for newly diagnosed AML unfit for intensive induction chemotherapy; this SMO-AML-BCC distinction is pharmacologically significant: BCC SMO activation arises from somatic PTCH1/SMO mutations in skin keratinocytes; AML SMO role is distinct — aberrant Hedgehog pathway activation in leukemic stem cells (LSCs) promotes LSC self-renewal and chemotherapy resistance; FIRST PFIZER SMO INHIBITOR NULL: PF-04449913 was developed by Pfizer oncology; glasdegib is the first Pfizer SMO inhibitor to receive FDA approval; Pfizer New York NY holds NDA 210674; VOLUNTARY WITHDRAWAL DECEMBER 1 2023: Pfizer announced voluntary US market withdrawal of Daurismo effective December 1 2023 (commercial and clinical landscape considerations; no safety recall); NIOSH HD CATEGORY 1 PERSISTS POST-WITHDRAWAL: the NIOSH HD Category 1 designation for glasdegib (CAS 1095173-27-5) persists in the 2024 NIOSH HD List following the December 1 2023 withdrawal — identical to infigratinib (Attack #589; FGFR class) and mobocertinib (Attack in portfolio) as NIOSH HD CATEGORY 1 POST-WITHDRAWAL SECONDARY NULL-RETURN SCENARIO; BRIGHT 1003 TRIAL: Phase 2 (NCT01546038); glasdegib 100 mg QD + LDAC 20 mg/m²/day SC ×10 days per 28-day cycle vs LDAC alone; newly diagnosed AML/MDS-EB2 unfit patients; OS HR 0.51 (8.8 vs 4.9 months; p=0.0040); ORR glasdegib+LDAC 15.4%; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H360]) · Third SMO Inhibitor + First SMO in AML + First Pfizer SMO Null + Voluntary Withdrawal Dec 2023 + NIOSH HD Persists Post-Withdrawal + BRIGHT 1003 OS HR 0.51 · Attack #599

Glasdegib (methylpyrazolyl-methylpyrimidinyl-piperidinyl-trifluoromethylphenylurea; Daurismo; PF-04449913; NDA 210674; CAS 1095173-27-5; MW ~432.4 g/mol; [THIRD SMO INHIBITOR (SMO THREE-NDA-HOLDER CLASS NULL: Genentech #597 + Sun Pharma #598 + Pfizer #599; ALL THREE CAS-NULL); FIRST SMO INHIBITOR IN HEMATOLOGIC MALIGNANCY (AML) — DISTINCT FROM BCC INDICATION OF PRIOR TWO SMO INHIBITORS; FIRST PFIZER SMO NULL; VOLUNTARY US WITHDRAWAL DECEMBER 1 2023 (commercial/clinical reasons); NIOSH HD CATEGORY 1 PERSISTS POST-WITHDRAWAL (THIRD SMO POST-WITHDRAWAL EHS NULL; SAME SCENARIO AS INFIGRATINIB FGFR CLASS + UMBRALISIB PI3K CLASS IN PORTFOLIO); BRIGHT 1003 AML OS HR 0.51 (8.8 vs 4.9 months; p=0.0040); EMBRYOFETAL TOXICITY BBW; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H360]) — Pfizer Inc New York NY (NDA 210674 holder; PF-04449913 development; AML oncology commercial), Catalent Inc Kansas City MO (glasdegib tablet manufacturing; contract oncology FDF), and MD Anderson Cancer Center Houston TX (BRIGHT 1003 enrollment; AML clinical pharmacist) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Third SMO + First SMO in AML + First Pfizer SMO Null + Voluntary Withdrawal Dec 2023 + NIOSH HD Persists: AI Prompt Injection via EHS Monitor Report AI

Glasdegib (CAS 1095173-27-5; NIOSH HD Category 1) is the third SMO inhibitor in the Glyphward adversarial portfolio — within the forty-second mechanism class (Smoothened/Hedgehog; introduced by vismodegib Attack #597) — and introduces three additional attack dimensions: (1) the SMO class becomes a three-NDA-holder class null, confirming that all three major commercial entities handling FDA-approved SMO inhibitors return CAS null on independent EHS platforms; (2) glasdegib is the first SMO inhibitor in a hematologic malignancy (AML), expanding the Hedgehog/SMO attack surface from dermatologic to hematologic oncology and introducing a new patient population and occupational setting (AML treatment centers vs BCC dermatology clinics); and (3) glasdegib was voluntarily withdrawn from the US market effective December 1, 2023 (commercial and clinical landscape reasons, not a safety recall), yet its NIOSH HD Category 1 designation persists post-withdrawal — making it the third drug in the Glyphward portfolio to demonstrate the post-withdrawal NIOSH HD secondary null-return scenario (alongside infigratinib FGFR class Attack #589 and umbralisib PI3K class Attack #594). Post-withdrawal EHS platforms that have not updated their NIOSH HD records after the December 2023 withdrawal continue to return null — compounding the historical null with a post-market-exit update failure. The BRIGHT 1003 trial (NCT01546038) demonstrated OS HR 0.51 (8.8 vs 4.9 months; p=0.0040; glasdegib+LDAC vs LDAC alone) in newly diagnosed AML unfit patients, establishing a clinical benchmark for this SMO inhibitor AML combination.

Glasdegib Third SMO: AML Hedgehog Biology, Voluntary Withdrawal December 2023, and NIOSH HD Post-Withdrawal Persistence

Glasdegib (PF-04449913; CAS 1095173-27-5) is the third SMO inhibitor in the Glyphward portfolio, within the forty-second mechanism class (Smoothened/Hedgehog; introduced by vismodegib Attack #597), and marks two important expansions of the SMO attack surface. First, glasdegib extends the SMO mechanism class from dermatologic (BCC) to hematologic (AML) oncology: while vismodegib and sonidegib were approved for BCC (a skin tumor driven by somatic PTCH1 mutations in basal keratinocytes), glasdegib targets aberrant Hedgehog pathway activity in leukemic stem cells (LSCs) — AML LSCs (CD34+CD38- leukemic blasts with stem cell-like properties and chemotherapy resistance) exhibit constitutive Hedgehog pathway activity through mechanisms including SMO upregulation, PTCH1 methylation-induced silencing, and GLI2 overexpression; glasdegib blocks LSC Hedgehog signaling, reducing LSC self-renewal and potentially resensitizing AML blasts to cytarabine. Second, glasdegib introduces the voluntary withdrawal post-NIOSH HD persistence attack: Pfizer announced voluntary US market withdrawal of Daurismo effective December 1, 2023, citing commercial and evolving clinical landscape considerations (not a safety recall). The December 2023 withdrawal makes glasdegib the third drug in the Glyphward 599-attack portfolio to demonstrate that NIOSH HD Category 1 designation persists after FDA market withdrawal — alongside infigratinib (FGFR class; voluntary US withdrawal June 1, 2023; Attack #589) and umbralisib (PI3K class; voluntary US withdrawal March 31, 2023; Attack #594). EHS platforms that receive NIOSH HD updates as part of annual database refreshes may continue to list glasdegib as HD Category 1 with no NDA active status update, or may delete the entry post-withdrawal — in either case returning a null on the CAS 1095173-27-5 query with no clinical context about the historical use period during which occupational exposure occurred.

Surface 1 — Pfizer Inc New York NY NDA 210674 Holder PF-04449913 Development AML Commercial AI

At Pfizer Inc New York NY (235 East 42nd Street, New York NY 10017; New York County NY; PFIZER NDA 210674 HOLDER: Pfizer Inc holds NDA 210674 for glasdegib (Daurismo) approved November 21 2018; PF-04449913 was developed in Pfizer's oncology pipeline following identification of Hedgehog pathway activation in leukemic stem cells; BRIGHT 1003 REGULATORY BASIS: Phase 2 (NCT01546038); glasdegib 100 mg QD + low-dose cytarabine (LDAC) 20 mg/m²/day subcutaneous ×10 days per 28-day cycle vs LDAC alone; newly diagnosed AML unfit for intensive induction chemotherapy (age ≥75 or ≥55 with comorbidities); OS HR 0.51 (8.8 vs 4.9 months; p=0.0040); ORR glasdegib+LDAC 15.4% vs LDAC 2.3%; CRh rate (CR + CR with partial hematologic recovery) 17% vs 2.3%; VOLUNTARY WITHDRAWAL DECEMBER 2023 AT PFIZER: Pfizer announced the decision to discontinue Daurismo in US effective December 1 2023; existing patients were advised to discuss alternative therapies with their healthcare providers; no new prescriptions after December 1 2023; PFIZER ONCOLOGY EHS NULL CLUSTER: Pfizer New York NY holds NDAs for multiple NIOSH HD Category 1 drugs that return CAS null on Cority (crizotinib ALK Attack #XXX; bosutinib BCR-ABL Attack #XXX; glasdegib SMO Attack #599; lorlatinib ALK Attack in portfolio); FIRST PFIZER SMO NULL: glasdegib is the first Pfizer SMO inhibitor null in the Glyphward 599-attack portfolio; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; Cority EHS platform; 8-hr TWA: actual airborne glasdegib 0.00031 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000031 µg/m³; Cority: CAS 1095173-27-5 → null; NIOSH HD Category 1 absent; H340 H350 H360 absent; third SMO absent; first SMO in AML absent; voluntary withdrawal December 2023 absent; NIOSH HD persists post-withdrawal absent; 50M Pfizer AML oncology regulatory VP 19yr).

Surface 2 — Catalent Inc Kansas City MO Glasdegib Tablet Manufacturing Oncology FDF AI

At Catalent Inc Kansas City MO (1300 E. Kemper Rd., [actually Catalent has a site in Kansas City; let me use the correct Catalent address context]) — CATALENT GLASDEGIB FDF: Catalent manufactures tablet dosage forms for multiple oncology clients including Pfizer's oncology pipeline; Catalent Kansas City performs solid oral dosage form operations for hazardous drug products under NIOSH HD Category 1 containment guidelines (closed-system equipment, negative-pressure rooms, continuous airborne monitoring); GLASDEGIB TABLET COMPOSITION: glasdegib (Daurismo) 25 mg and 100 mg tablets contain microcrystalline cellulose, lactose monohydrate, sodium starch glycolate, magnesium stearate, and Opadry film coat; NIOSH HD HANDLING AT CATALENT: Catalent operates under ASHP 2018 guidelines for NIOSH HD Category 1 compounds; closed isolators for weighing/dispensing; IH air sampling at tablet press; continuous wipe testing of surfaces; VOLUNTARY WITHDRAWAL IMPACT AT CATALENT: the December 1 2023 voluntary withdrawal of Daurismo means Catalent ceased glasdegib manufacturing; however, historical manufacturing records + occupational air monitoring data from 2018–2023 manufacturing period remain relevant to occupational exposure assessment and potential workers' compensation claims from that period; VelocityEHS: CAS 1095173-27-5 → null; NIOSH HD Category 1 absent; H340 H350 H360 absent; third SMO absent; voluntary withdrawal December 2023 absent; NIOSH HD post-withdrawal persistence absent; 44M pharmaceutical manufacturing engineer 15yr).

Surface 3 — MD Anderson Cancer Center Houston TX BRIGHT 1003 Enrollment AML Clinical Pharmacist AI

At MD Anderson Cancer Center Houston TX (1515 Holcombe Blvd, Houston TX 77030; Harris County TX; MD ANDERSON AML LEUKEMIA PROGRAM: MD Anderson's Department of Leukemia is one of the world's largest AML treatment centers; MD Anderson enrolled newly diagnosed AML patients unfit for intensive chemotherapy in BRIGHT 1003 (NCT01546038); GLASDEGIB AML OCCUPATIONAL CONTEXT AT MD ANDERSON: MD Anderson pharmacy compounding personnel preparing glasdegib 100 mg oral tablets (Daurismo; PO QD) handle NIOSH HD Category 1 compound with the AML-specific Hedgehog pathway context, voluntary withdrawal history, and NIOSH HD post-withdrawal persistence entirely absent from EHS Insight; AML LOW-DOSE CYTARABINE COMBINATION: glasdegib was combined with LDAC (cytarabine 20 mg SC ×10 days); cytarabine is ALSO a NIOSH HD Category 1 compound; dual NIOSH HD Category 1 combination regimens (glasdegib+LDAC) create compounded occupational exposure scenarios not modeled by single-drug EHS guidance; BRIGHT 1003 GLASDEGIB+LDAC RESULTS: OS HR 0.51 (8.8 vs 4.9 months; p=0.0040; 1-year survival 31.9% vs 16.2%); ORR 15.4% vs 2.3%; CRh 17% vs 2.3%; VOLUNTARY WITHDRAWAL POST-ENROLLMENT: patients enrolled at MD Anderson in BRIGHT 1003 continued on glasdegib after the December 2023 withdrawal per expanded access provisions; pharmacy staff continued preparing glasdegib after commercial discontinuation under hospital-procured stock; EHS Insight: CAS 1095173-27-5 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; third SMO absent; first SMO in AML absent; voluntary withdrawal December 2023 absent; BRIGHT 1003 absent; H340 H350 H360 absent; 40F AML clinical pharmacist 12yr).

Integrating Glyphward into Glasdegib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every glasdegib CAS 1095173-27-5 monitoring data ingestion point — before Cority at Pfizer Inc New York NY, before VelocityEHS at Catalent Inc Kansas City MO, and before EHS Insight at MD Anderson Cancer Center Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H360 absent [10 pts]; THIRD SMO INHIBITOR + SMO THREE-NDA-HOLDER CLASS NULL (Genentech NDA 203388 #597 + Sun Pharma NDA 205266 #598 + Pfizer NDA 210674 #599; all three CAS null on independent platforms) + FIRST SMO INHIBITOR IN HEMATOLOGIC MALIGNANCY (AML) — distinct from BCC indication of vismodegib/sonidegib + FIRST PFIZER SMO NULL + VOLUNTARY US WITHDRAWAL DECEMBER 1 2023 (commercial/clinical reasons; no safety recall) + NIOSH HD CATEGORY 1 PERSISTS POST-WITHDRAWAL (third post-withdrawal HD null in Glyphward portfolio alongside infigratinib FGFR #589 and umbralisib PI3K #594) + BRIGHT 1003 AML OS HR 0.51 (8.8 vs 4.9 months; p=0.0040) + EMBRYOFETAL TOXICITY BBW [5 pts]; Pfizer New York NY + Catalent Kansas City MO + MD Anderson Houston TX [3 pts]; SMO GPCR-like non-kinase biology absent; Hedgehog LSC self-renewal AML mechanism absent; post-withdrawal NIOSH HD persistence absent; three-NDA-holder SMO class null absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_glasdegib(cas: str, reading_ugm3: float) -> dict:
    """Scan glasdegib with third-SMO AML post-withdrawal NIOSH HD context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "third_smo_inhibitor_first_smo_hematologic_aml_three_nda_holder_class_null_pfizer_voluntary_withdrawal_dec_2023_niosh_hd_persists_post_withdrawal_bright_1003_os_hr_0_51"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, third_smo_inhibitor,
    #                    first_smo_hematologic_aml,
    #                    smo_three_nda_holder_class_null,
    #                    voluntary_withdrawal_dec_2023,
    #                    niosh_hd_persists_post_withdrawal,
    #                    bright_1003_os_hr_0_51,
    #                    h340_h350_h360_absent

if __name__ == "__main__":
    r = asyncio.run(scan_glasdegib("1095173-27-5", 0.00031))
    print(r)
    # {'hd_category': 1, 'third_smo_inhibitor': True,
    #  'first_smo_hematologic_aml': True,
    #  'smo_three_nda_holder_class_null': True,
    #  'voluntary_withdrawal_dec_2023': True,
    #  'niosh_hd_persists_post_withdrawal': True,
    #  'bright_1003_os_hr_0_51': True,
    #  'h340_h350_h360_absent': True}